Malaria booster vaccine continues to meet WHO-specified 75% efficacy goal

Published on September 8, 2022

Researchers from the University of Oxford and their partners have today reported new findings from their Phase 2b trial following the administration of a booster dose of the candidate malaria vaccine, R21/Matrix-M™ – which previously demonstrated high-level efficacy of 77% over the following 12 months in young west African children in 2021.

In their findings (reported in The Lancet Infectious Diseases), they found that a vaccine booster dose at one year following a primary three-dose regime maintained high efficacy against malaria, and continued to meet the World Health Organization’s Malaria Vaccine Technology Roadmap goal of a vaccine with at least 75% efficacy.
Continue reading on website
Other news

Springer Link: Theorising the Fiduciary – Ontology and Ethics

September 7, 2022
Cambridge Judge Business School is mentioned in this article about the omnipresence of the fiduciary in business organisations.Read the full article [link.springer.com]The post Springer Link: Theorising the Fiduciary – Ontology and Ethics appeared first on Cambridge Judge Business School.

Oxford researchers develop new AI to enable autonomous vehicles to adapt to challenging weather conditions

September 8, 2022
Researchers at Oxford University’s Department of Computer Science, in collaboration with colleagues from Bogazici University, Turkey, have developed a novel artificial intelligence (AI) system to enable autonomous vehicles (AVs) to achieve safer and more reliable navigation capability, especially under adverse weather conditions.